Immunic, Inc. (IMUX) Revenue History
Annual and quarterly revenue from 2011 to present
IMUX Revenue Over Time (2011–2025)
IMUX Revenue Growth History
0 of 1 years with positive growth- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- -100.0%
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
IMUX Revenue Analysis (2011–2025)
Current Revenue & Growth
As of June 12, 2026, Immunic, Inc. (IMUX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
IMUX's historical revenue data shows various trends over time. Immunic, Inc.'s highest annual revenue of $6,315 was recorded in 2016.
Peer Comparison
Compared to Healthcare sector peers — including ARQT (+95.3% YoY), VNDA (+8.2% YoY), and ACAD (+9.9% YoY). Compare IMUX vs ARQT →
IMUX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 IMUXCurrent | $0 | - | - | - | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 VNDA | $216M | +8.2% | -2.7% | -70.0% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 IDYA | $219M | +3118.1% | +62.1% | -72.8% |
IMUX Historical Revenue Data (2011–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-103,228,000 | - |
| 2024 | $0 | - | $0 | - | $-98,052,000 | - |
| 2023 | $0 | - | $0 | - | $-99,223,000 | - |
| 2022 | $0 | - | $0 | - | $-119,488,000 | - |
| 2021 | $0 | - | $0 | - | $-91,665,000 | - |
| 2020 | $0 | - | $0 | - | $-48,971,000 | - |
| 2019 | $0 | - | $-50,000 | - | $-37,032,000 | - |
| 2018 | $0 | - | $-15,000 | - | $-42,024,000 | - |
| 2017 | $0 | -100.0% | $-998,000 | - | $-52,655,000 | - |
| 2016 | $6K | - | $-1,801,685 | -28529.7% | $-41,266,000 | -653447.6% |
| 2015 | $0 | - | $-1,328,000 | - | $-52,120,000 | - |
| 2014 | $0 | - | $0 | - | $-50,342,000 | - |
| 2013 | $0 | - | $0 | - | $-31,402,000 | - |
| 2012 | $0 | - | $0 | - | $-9,580,000 | - |
| 2011 | $0 | - | $0 | - | $-8,581,000 | - |
What if you invested $1,000 in IMUX back in 2011?
Total return with dividends reinvested · 15+ years of data
Calculate ReturnsHow much would $100/month in IMUX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMUX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMUX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowIMUX — Frequently Asked Questions
Quick answers to the most common questions about buying IMUX stock.
Is IMUX's revenue growth accelerating or slowing?
IMUX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is IMUX's revenue history from 2011 to 2026?
Immunic, Inc. (IMUX) revenue history spans 2011 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is IMUX's long-term revenue growth rate (CAGR)?
Immunic, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for IMUX.
Why does IMUX's quarterly revenue fluctuate?
IMUX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Immunic, Inc.'s revenue data from 2011 to 2026 shows full historical quarterly detail on this page.
How is IMUX's revenue distributed by segment?
IMUX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does IMUX's revenue compare to industry peers?
Immunic, Inc. (IMUX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.